This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Liminal BioSciences Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Liminal BioSciences.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	35.4%
Tasso di crescita dei ricavi	-149.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	10 Apr 2023

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

DB:PJ2 - Stime future degli analisti e dati finanziari passati (CAD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
12/31/2022	0	-29	-32	-32	N/A
9/30/2022	0	-31	-38	-38	N/A
6/30/2022	1	-35	-84	-84	N/A
3/31/2022	0	-42	-86	-86	N/A
12/31/2021	1	-44	-100	-100	N/A
9/30/2021	1	-48	-114	-114	N/A
6/30/2021	1	-49	-75	-74	N/A
3/31/2021	1	-35	-75	-74	N/A
12/31/2020	1	-48	-78	-76	N/A
9/30/2020	1	-75	-87	-85	N/A
6/30/2020	2	-94	-86	-85	N/A
3/31/2020	3	-232	-109	-105	N/A
12/31/2019	1	-150	-104	-99	N/A
9/30/2019	-8	-299	-95	-89	N/A
6/30/2019	3	-298	-90	-84	N/A
3/31/2019	23	-194	-73	-68	N/A
12/31/2018	25	-197	-88	-82	N/A
9/30/2018	43	-131	-91	-85	N/A
6/30/2018	55	-118	-112	-105	N/A
3/31/2018	39	-115	-128	-120	N/A
12/31/2017	22	-112	-133	-123	N/A
9/30/2017	37	-109	-139	-129	N/A
6/30/2017	16	-119	-130	-118	N/A
3/31/2017	16	-112	-127	-114	N/A
12/31/2016	16	-101	-113	-98	N/A
9/30/2016	26	-74	N/A	-76	N/A
6/30/2016	28	-58	N/A	-66	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if PJ2's forecast earnings growth is above the savings rate (0.2%).

Guadagni vs Mercato: Insufficient data to determine if PJ2's earnings are forecast to grow faster than the German market

Guadagni ad alta crescita: Insufficient data to determine if PJ2's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: PJ2 is forecast to have no revenue next year.

Ricavi ad alta crescita: PJ2 is forecast to have no revenue next year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if PJ2's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Liminal BioSciences Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Liminal BioSciences Inc.(NasdaqCM:LMNL) dropped from NASDAQ Composite Index

Structured Alpha LP, a fund managed by Thomvest Ventures, Inc. completed the acquisition of remaining 38.8% stake in Liminal BioSciences Inc. (DB:PJ2).

Liminal Biosciences' Common Shares to Be Delisted from Nasdaq

Liminal BioSciences Regains Compliance with NASDAQ Minimum Bid Price Requirement

Liminal BioSciences Inc. Appoints Gary Bridger as Interim Chief Scientific

Liminal BioSciences Inc. to Report Q3, 2022 Results on Nov 09, 2022

Liminal Biosciences Announces Listing Transfer to The Nasdaq Capital Market from The Nasdaq Global Market

Liminal BioSciences Inc. (DB:PJ2N) acquired the remaining 23% stake in Pathogen Removal and Diagnostic Technologies, Inc. for $30.

Liminal BioSciences Inc. Announces Discontinuation of Fezagepras Development

Liminal Biosciences Announces First Subject Dosed in Phase 1A Single Ascending Dose Clinical Trial of Fezagepras

Liminal BioSciences Inc. to Report Q1, 2022 Results on May 10, 2022

Liminal BioSciences Inc., Annual General Meeting, Jun 06, 2022

Liminal BioSciences Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

Ocugen, Inc. (NasdaqCM:OCGN) signed a non-binding letter of intent to acquire a manufacturing site in Belleville, Ontario from Liminal BioSciences Inc. (DB:PJ2N).

Kedrion S.p.A. signed a share purchase agreement to acquire Prometic Bioproduction Inc. and Prometic Biotherapeutics Inc. from Liminal BioSciences Inc. (DB:PJ2N).

Liminal BioSciences Inc. Announces FDA Approval for its Biologics License Application for Ryplazim® (Plasminogen, Human-Tvmh)

Liminal BioSciences Inc. Provides an Update on Currently Planned Clinical Activities for Fezagepras

Liminal BioSciences Inc. Provides an Update Regarding the Company’s Corporate Strategy for Its Small Molecule Therapeutics and Plasma-Derived Based Therapeutics Platforms

Liminal BioSciences Inc. Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

Liminal BioSciences Inc. Announces Executive Changes

Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(plasminogen) BLA

Liminal BioSciences Inc. to Report Q3, 2020 Results on Nov 12, 2020

Liminal BioSciences to Voluntarily Delist from the Toronto Stock Exchange

Liminal BioSciences Inc. announced that it has received CAD 2.4 million in funding from Amorchem, Genesys Capital Partners Inc.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita